Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 3
2012 1
2015 1
2017 1
2019 1
2020 3
2021 6
2022 2
2023 3
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Tenofovir nephrotoxicity: 2011 update.
Fernandez-Fernandez B, Montoya-Ferrer A, Sanz AB, Sanchez-Niño MD, Izquierdo MC, Poveda J, Sainz-Prestel V, Ortiz-Martin N, Parra-Rodriguez A, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. Fernandez-Fernandez B, et al. Among authors: montoya ferrer a. AIDS Res Treat. 2011;2011:354908. doi: 10.1155/2011/354908. Epub 2011 Jun 7. AIDS Res Treat. 2011. PMID: 21716719 Free PMC article.
Cost-efficiency of laboratory testing among psychiatric inpatients.
Lopez-Castroman J, Blasco-Fontecilla H, Paz-Yepes M, Montoya-Ferrer A, De Leon-Martinez V, Alvarez R, Baca-Garcia E. Lopez-Castroman J, et al. Among authors: montoya ferrer a. Int J Psychiatry Med. 2012;44(3):211-24. doi: 10.2190/PM.44.3.c. Int J Psychiatry Med. 2012. PMID: 23586277
Chemsex in HIV pre-exposure prophylaxis users: Assessment of mood disorders and addictive behavior.
Peyriere H, Jacquet JM, Peries M, Tribout V, Broche B, Mauboussin JM, Makinson A, Perrollaz C, Ferreyra M, Rouanet I, Montoya-Ferrer A, El-Majjaoui S, Corriol-Bonifas F, Fraisse T, Grau F, Laureillard D, Nagot N, Reynes J, Donnadieu-Rigole H. Peyriere H, et al. Among authors: montoya ferrer a. Fundam Clin Pharmacol. 2023 Jun;37(3):639-649. doi: 10.1111/fcp.12854. Epub 2022 Dec 1. Fundam Clin Pharmacol. 2023. PMID: 36403123
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Deschanvres C, Reynes J, Lamaury I, Rey D, Palich R, Bani-Sadr F, Robineau O, Duvivier C, Hocqueloux L, Cuzin L, Joly V, Raffi F, Cabie A, Allavena C; Dat’AIDS Study Group. Deschanvres C, et al. J Antimicrob Chemother. 2021 Dec 24;77(1):196-204. doi: 10.1093/jac/dkab367. J Antimicrob Chemother. 2021. PMID: 34651192
Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
Palich R, Allavena C, Peytavin G, Soulie C, Tubiana R, Weiss L, Montoya Ferrer A, Duvivier C, Bouchaud O, Bottero J, Durand A, Lê MP, Marcelin AG, Dudoit Y, Assoumou L, Katlama C; ETRAL QD study group. Palich R, et al. Among authors: montoya ferrer a. J Antimicrob Chemother. 2021 Jan 19;76(2):477-481. doi: 10.1093/jac/dkaa423. J Antimicrob Chemother. 2021. PMID: 33099638 Clinical Trial.
20 results